NCT06965569 - Multiple Ascending Dose Phase 1 Study of ALA-3000 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

October 27, 2025

Study Completion Date

October 27, 2025

Conditions

Treatment Resistant Depression

Interventions

DRUG

ALA-3000

Subcutaneous injection

DRUG

Placebo

Subcutaneous injection

DRUG

escitalopram, sertraline, duloxetine or venlafaxine XR

Newly initiated oral AD selected from SSRI (escitalopram or sertraline) or SNRI (duloxetine or venlafaxine XR) will be given daily

Trial Locations (4)

RECRUITING

Neuro-Behavioral Clinical Research, Inc, North Canton

RECRUITING

Arch Clinical Trials, St Louis

RECRUITING

Pillar Clinical Research, Little Rock

RECRUITING

Clinilabs Drug Development Corporation, Eatontown